title: Inhibitory effects of paeoniflorin on lysophosphatidylcholine-induced             inflammatory factor production in human umbilical vein endothelial cells.
abstract: Lysophosphatidylcholine (LPC) plays an important role in atherosclerosis through initiation of endothelial inflammation response. Paeoniflorin (PEF), isolated from the dry root of Paeonia, has been reported to exert an anti-inflammatory effect, but the exact mechanism is not fully understood. The aim of this study was to investigate the inhibitory effects of PEF on LPC-induced inflammatory factor production and the underlying mechanisms. In human umbilical vein endothelial cells (HUVECs), different concentrations (1, 10 or 100 µmol/l) of PEF were added 2 h prior to exposure to LPC (10 mg/l) for 24 h. The results showed that PEF significantly inhibited LPC-induced inflammatory factor production. In addition, PEF was also able to suppress the enhanced high mobility group box-1 (HMGB1) expression and release, upregulated expression of receptor for advanced glycation end product (RAGE), Toll-like receptor (TLR)-2 and TLR-4, and increased nuclear factor-κB (NF-κB) activity induced by LPC. Our results suggest that PEF suppresses LPC-induced inflammatory factor production through inhibition of the HMGB1-RAGE/TLR-2/TLR-4-NF-κB pathway.
authors.affiliation: Department of Pharmacy, Ruikang Hospital, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi 530011, P.R. China. jianzhe_li@yahoo.com
authors.forename: Jian-Zhe
authors.initials: JZ
authors.lastname: Li
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Wu
authors.forename: Shu-Yi
authors.initials: SY
authors.lastname: Yu
authors.forename: Qing-Rui
authors.initials: QR
authors.lastname: Shao
authors.forename: Xiao-Min
authors.initials: XM
authors.lastname: Dong
mesh_terms: D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology*; D001565:Benzoates / Q000302:isolation & purification / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000302:isolation & purification / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D024243:HMGB1 Protein / Q000235:genetics / Q000276:immunology; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008244:Lysophosphatidylcholines / Q000276:immunology*; D039821:Monoterpenes; D016328:NF-kappa B / Q000276:immunology; D029596:Paeonia / Q000737:chemistry; D051195:Toll-Like Receptor 2 / Q000235:genetics; D051197:Toll-Like Receptor 4 / Q000235:genetics; D006027:Glycosides
chemical_list: D000893:Anti-Inflammatory Agents; D001565:Benzoates; D001952:Bridged-Ring Compounds; D005960:Glucosides; D024243:HMGB1 Protein; D008244:Lysophosphatidylcholines; D039821:Monoterpenes; D016328:NF-kappa B; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; C495345:TLR4 protein, human; C015423:peoniflorin; D006027:Glycosides